Cell death in photoreceptor cells is reversible, study finds
Peer-Reviewed Publication
Updates every hour. Last Updated: 7-Jun-2026 16:16 ET (7-Jun-2026 20:16 GMT/UTC)
A retinal image could help doctors quickly distinguish between similar neurodegenerative diseases such as ALS and Alzheimer’s disease, and with remarkable accuracy, according to new research.
Researchers from the University of Waterloo are leading the development of a fast, non-invasive, and affordable diagnostic tool. There is currently no objective diagnostic test for ALS or Frontotemporal Lobular Dementia (FTLD-TDP), in which the protein TDP-43 forms deposits in the spinal cord and brain, respectively.
Prior authorization, a process that requires physicians to obtain approval from health care insurers before certain treatments are covered, may keep patients from filling prescriptions for two critical heart failure drugs, a new study shows.
Berberine is sometimes promoted in social media as a “natural Ozempic,” but scientific evidence does not support this comparison. A review by researchers from Wroclaw Medical University shows that this plant alkaloid does not act like incretin drugs and does not regulate metabolism through a single hormonal mechanism.
Current research indicates that berberine mainly affects the intestinal environment, influencing gut microbiota, inflammatory processes, and the integrity of the intestinal barrier. Its metabolic effects are therefore indirect and strongly dependent on the composition of the microbiota, which may explain why responses differ between individuals.
The authors also note that the compound’s low systemic bioavailability may favor its local action in the intestine, where it is metabolized by gut microorganisms. At the same time, berberine can cause gastrointestinal side effects and interact with several medications, which means it should not be treated as a universal metabolic supplement or a substitute for medical therapy.
Adherence to Clinical Practice Guidelines in the management of rare cancers remains inconsistent across Europe despite demonstrably improving patient outcomes, shows an analysis jointly conducted by ESMO and EURACAN, the European Reference Network (ERN) for rare cancers.
A research team from the University of Tokyo and Tokyo University of Agriculture and Technology uncovered a new mechanism of Yaku’amide B, a deep-sea sponge-derived natural product. Using photoaffinity labeling, they found that yaku’amide B transiently binds CD9, inducing its degradation, in addition to inhibiting ATP synthase. This dual action suppresses cancer cell proliferation and migration, opening new avenues for anticancer drug development and protein degradation strategies.